Can immune cell therapy stop type 1 diabetes before it starts?
Disease control
Recruiting now
This study tests whether a combination of special immune cells (Tregs) and an antibody drug (rituximab) can delay or prevent type 1 diabetes in children aged 6-16 who are at high risk but still produce insulin normally. About 150 participants will be randomly assigned to one of f…
Phase: PHASE2 • Sponsor: PolTREG S.A. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC